Last updated: 2026-09-06 23:54:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ARS Pharmaceuticals, Inc. (SPRY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5,62, with a market capitalization of $578,78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,91 to $13,15. This page covers its latest market performance, valuation, price trends and company information.
$578,78M | |
$5,60 | |
$18,90 | |
$2,55 | |
$5,67 | |
687,61K | |
-- | |
-- | |
$13,15 | |
$4,91 | |
-- | |
-- |
ARS Pharmaceuticals, Inc. (SPRY) last closed at $5,67 as of 2026-09-05 00:00:00, unchanged from the previous close of $5,67.
During the latest regular trading session, SPRY traded between $2,55 and $18,90, with a volume of 687,61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, ARS Pharmaceuticals, Inc. (SPRY) moved from $5,87 to $5,62, representing a decline of 4,34% ($0,25).
The stock traded between $5,54 and $5,92 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1,27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 8,6%
SPRY is currently trading at $5,62, placing it 8,6% of the way from its 52-week low of $4,91 to its 52-week high of $13,15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 200 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ARS Pharmaceuticals, Inc. (SPRY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.